PF573228
PF573228 is a selective serotonin 5-HT2A receptor partial agonist that is under development for the treatment of anxiety disorders. It was discovered by Pfizer and is currently in clinical trials. The drug is designed to modulate the activity of serotonin, a neurotransmitter involved in mood regulation, without the sedating side effects associated with some other serotonin receptor agonists.
The development of PF573228 is focused on its potential to treat generalized anxiety disorder (GAD), social
Clinical trials for PF573228 have shown promising results in reducing anxiety symptoms in patients. The drug
One of the key advantages of PF573228 is its potential to be well-tolerated, with a lower risk
However, like any new medication, PF573228 is still in the early stages of development. Further clinical trials
In summary, PF573228 is a selective serotonin 5-HT2A receptor partial agonist in development for the treatment